Discontinued — last reported Q2 '21
Debt - Unamortized Discount (Premium) and Issuance Costs, Net
West Pharmaceutical Services Debt - Unamortized Discount (Premium) and Issuance Costs, Net remained flat by 0.0% to $200.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.0%, from $400.00K to $200.00K. Over 5 years (FY 2020 to FY 2025), Debt - Unamortized Discount (Premium) and Issuance Costs, Net shows a downward trend with a -16.7% CAGR.
Analysis
How to read this metric
Changes reflect the issuance of new debt or the amortization of existing discounts/premiums, impacting future interest expense.
Detailed definition
This represents the net adjustment to the face value of debt, accounting for the difference between the issuance price a...
Peer comparison
Standard accounting adjustment for any company with significant long-term debt instruments on its balance sheet.
debt_unamortized_discount_premium_issuance_costsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $500.00K | $500.00K | $500.00K | $400.00K | $400.00K | $400.00K | $300.00K | $300.00K | $300.00K | $200.00K | $200.00K | $200.00K | $100.00K | $400.00K | $400.00K | $400.00K | $400.00K | $300.00K | $200.00K | $200.00K |
| QoQ Change | — | +0.0% | +0.0% | -20.0% | +0.0% | +0.0% | -25.0% | +0.0% | +0.0% | -33.3% | +0.0% | +0.0% | -50.0% | +300.0% | +0.0% | +0.0% | +0.0% | -25.0% | -33.3% | +0.0% |
| YoY Change | — | — | — | — | -20.0% | -20.0% | -40.0% | -25.0% | -25.0% | -50.0% | -33.3% | -33.3% | -66.7% | +100.0% | +100.0% | +100.0% | +300.0% | -25.0% | -50.0% | -50.0% |
Debt - Unamortized Discount (Premium) and Issuance Costs, Net at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's debt - unamortized discount (premium) and issuance costs, net?
- West Pharmaceutical Services (WST) reported debt - unamortized discount (premium) and issuance costs, net of $200.00K in Q1 2026.
- How has West Pharmaceutical Services's debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
- West Pharmaceutical Services's debt - unamortized discount (premium) and issuance costs, net decreased by 50.0% year-over-year, from $400.00K to $200.00K.
- What is the long-term trend for West Pharmaceutical Services's debt - unamortized discount (premium) and issuance costs, net?
- Over 5 years (2020 to 2025), West Pharmaceutical Services's debt - unamortized discount (premium) and issuance costs, net has grown at a -16.7% compound annual growth rate (CAGR), from $500.00K to $200.00K.
- What does debt - unamortized discount (premium) and issuance costs, net mean?
- The net adjustment to debt value representing issuance costs and the difference between issuance price and face value.